Amneal Pharmaceuticals Inc
NYSE:AMRX
Amneal Pharmaceuticals Inc
Operating Income
Amneal Pharmaceuticals Inc
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Amneal Pharmaceuticals Inc
NYSE:AMRX
|
Operating Income
$274.8m
|
CAGR 3-Years
24%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
27%
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Income
$23.4B
|
CAGR 3-Years
3%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Income
$10.5B
|
CAGR 3-Years
14%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
Pfizer Inc
NYSE:PFE
|
Operating Income
$13.1B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
-3%
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Income
$6.6B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-2%
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Income
$10.3B
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
6%
|
See Also
What is Amneal Pharmaceuticals Inc's Operating Income?
Operating Income
274.8m
USD
Based on the financial report for Dec 31, 2023, Amneal Pharmaceuticals Inc's Operating Income amounts to 274.8m USD.
What is Amneal Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 10Y
27%
Over the last year, the Operating Income growth was 38%. The average annual Operating Income growth rates for Amneal Pharmaceuticals Inc have been 24% over the past three years , -1% over the past five years , and 27% over the past ten years .